Harmony Biosciences Holdings, Inc..
HRMY.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Harmony Biosciences Holdings, Inc. is a pharmaceutical company focused on developing and commercializing innovative therapies for patients with rare neurological diseases and other central nervous system (CNS) disorders. Their primary product is WAKIX (pitolisant), a selective histamine 3 (H3) recep...Show More
Better Health for All
10
Harmony Biosciences' core business delivers exceptional health benefits, focusing on developing and commercializing innovative therapies for rare neurological diseases.
1
Its product, WAKIX, is the first and only non-scheduled FDA-approved treatment for narcolepsy in adults and pediatric patients 6 years and older, having received orphan drug and breakthrough therapy designations.
2
The company has exceptional equity programs, with its 'Progress at the Heart' program funding 13 initiatives in two years and 'Patients at the Heart' funding 22 initiatives over four years, with a maximum funding of $50,000 per application.
3
Harmony Biosciences provides excellent risk transparency, offering comprehensive disclosure systems for WAKIX, including contraindications, warnings, adverse reactions, and drug interactions, and encourages reporting of suspected adverse reactions.
4
The company demonstrates comprehensive investment in healthcare education, supporting STEM education, medical education grants, and programs to increase awareness and decrease time to diagnosis for rare neurological diseases.
5
Harmony Biosciences also has comprehensive mental health programs, including sessions with psychologists focused on sleep medicine and addressing conditions like Fragile X syndrome.
6
However, the company exhibits substantial patent inflexibility, with a settlement agreement allowing a generic version of WAKIX no earlier than January 2030, and potential exclusivity for next-generation formulations until 2044.
7
The company maintains excellent ethical frameworks for clinical trials, adhering to legal and regulatory requirements like Good Clinical Practice (GCP) and ensuring investigator independence for Investigator Sponsored Studies.
8
Fair Money & Economic Opportunity
0
Harmony Biosciences Holdings, Inc. is a pharmaceutical company focused on developing and commercializing therapies for rare neurological diseases. The company does not offer lending, deposit, or other financial services to consumers.
1
Therefore, none of the KPIs under the 'Fair Money & Economic Opportunity' value are applicable, as they are designed to assess financial institutions and their direct impact on financial inclusion, lending practices, and economic opportunity through financial products. While the company launched a grant program to address healthcare inequities,
2
this does not constitute community finance or profit-sharing in the context of financial services as defined by the rubric.
Fair Pay & Worker Respect
30
Harmony Biosciences reported a CEO to median employee pay ratio of 29:1 in 2024, with the median employee earning $249,161.
1
Employee survey results indicate high engagement, with 94% of employees feeling welcomed and positive about the company's community contribution, 93% having access to needed resources, and 92% feeling they could take time off and made a difference.
2
The company states it is in compliance with California Health & Safety Code, Section 119402, and no regulatory actions, violations, fines, or compliance issues are mentioned in the provided articles.
3
Fair Trade & Ethical Sourcing
0
No evidence available to assess Harmony Biosciences Holdings, Inc. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
-40
The company has a whistleblower policy implemented through NAVEX Global’s EthicsPoint system, with a corporate compliance hotline.
1
The audit committee is responsible for establishing procedures for confidential anonymous submissions.
2
The board of directors includes two non-independent members (the President and CEO, and the Chairman), with all other directors being independent.
3
The company has adopted a Comprehensive Compliance Program for its business and operations in California, which includes an annual spending limit of $2,500 on meals and promotional items for healthcare professionals.
4
The company is subject to U.S. and foreign anti-corruption laws, including the FCPA.
5
Kind to Animals
0
No information regarding Harmony Biosciences Holdings, Inc.'s animal welfare practices, animal testing policies, use of animal-free alternatives, or engagement in animal-related initiatives was found in the provided articles.
1
No War, No Weapons
0
The provided articles, which include general ESG data, do not contain any specific information or quantitative data regarding Harmony Biosciences Holdings, Inc.'s involvement in arms manufacturing, military contracts, dual-use technologies, sales to sanctioned regimes, or any other activities relevant to the 'No War, No Weapons' ethical value.
1
Therefore, no assessment can be made against the specified KPIs.
Planet-Friendly Business
-20
Harmony Biosciences reported 2022 Greenhouse Gas Emissions of 1,247 metric tons CO2e.
1
In 2022, 22.5% of the company's operational energy consumption was sourced from renewables.
2
The company achieved a waste diversion rate of 68% in 2022.
3
Harmony Biosciences maintains 100% compliance with EPA pharmaceutical manufacturing guidelines, indicating zero environmental compliance violations.
4
In 2022, the company conducted 12 environmental impact assessments.
5
The company also reported a 4.8% reduction in water consumption in 2022, but revenue data is not available to calculate water use per revenue unit.
6
Respect for Cultures & Communities
0
Based on the provided documents, there is insufficient evidence to assess Harmony Biosciences' alignment with the value of "Respect for Cultures & Communities." The articles primarily focus on the company's ethics and compliance programs, patient assistance programs, and philanthropic activities related to rare neurological diseases
1
,
2
,
3
,
4
,
5
,
6
,
7
,
8
,
9
,
10
. While the company supports patient organizations and community initiatives, there is no specific information available regarding formal partnerships with indigenous or local community groups, revenue reinvestment in local communities, cultural appropriation incidents, cultural impact assessment protocols, local employment ratios, or other key metrics associated with this value. Therefore, a neutral score of 0 is assigned due to the lack of relevant evidence.
Safe & Smart Tech
10
Harmony Biosciences has not documented any data breaches or incidents of unauthorized data use.
1
The company's Privacy Notice, effective April 1, 2025, outlines standard user rights including access, erasure, rectification, and data portability.
2
Harmony Biosciences has a Comprehensive Compliance Program for its California operations and is subject to U.S. federal and state health information privacy, security, and data breach notification laws, as well as other federal healthcare regulations.
3
The company employs third parties for penetration testing and vulnerability management, and its Harmony Endpoint system includes automatic scanning of all devices to detect vulnerabilities and offers patch management capabilities.
4
Zero Waste & Sustainable Products
-20
Harmony Biosciences Holdings, Inc. has no mentioned regulatory actions, violations, fines, or compliance issues related to waste disposal.
1
For all other KPIs concerning waste management and sustainable products, the available articles explicitly state that no data is available, including waste diversion rates, product recyclability, packaging sustainability, and waste reduction targets.
2